Microfabrication technology for pancreatic cell encapsulation

The inadequacy of conventional insulin therapy for the treatment of Type I diabetes has stimulated research on several therapeutic alternatives, including insulin pumps and controlled-release systems for insulin. One of the most physiological alternatives to insulin injections is the transplantation...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on biological therapy Vol. 2; no. 6; p. 633
Main Author Desai, Tejal A
Format Journal Article
LanguageEnglish
Published England 01.08.2002
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The inadequacy of conventional insulin therapy for the treatment of Type I diabetes has stimulated research on several therapeutic alternatives, including insulin pumps and controlled-release systems for insulin. One of the most physiological alternatives to insulin injections is the transplantation of insulin-secreting cells. It is the beta-cells of the islets that secrete insulin in response to increasing blood glucose concentrations. Ideally, transplantation of such cells (allografts or xenografts) could restore normoglycaemia. However, as with most tissue or cellular transplants, the cellular grafts, particularly xenografts, are subject to immunorejection in the absence of chronic immunosuppression. Thus, it is of great interest to develop new technologies that may be used for insulin delivery or pancreatic cell transplantation. This review describes a new approach to cellular delivery based on micro- and nanotechnology. Utilising this approach, nanoporous biocapsules are bulk and surface micromachined to present uniform and well-controlled pore sizes as small as 7 nm, tailored surface chemistries and precise microarchitectures, in order to provide immunoisolating microenvironments for cells. Such a design may overcome some of the limitations associated with conventional encapsulation and delivery technologies, including chemical instabilities, material degradation or fracture and broad membrane pore sizes.
AbstractList The inadequacy of conventional insulin therapy for the treatment of Type I diabetes has stimulated research on several therapeutic alternatives, including insulin pumps and controlled-release systems for insulin. One of the most physiological alternatives to insulin injections is the transplantation of insulin-secreting cells. It is the beta-cells of the islets that secrete insulin in response to increasing blood glucose concentrations. Ideally, transplantation of such cells (allografts or xenografts) could restore normoglycaemia. However, as with most tissue or cellular transplants, the cellular grafts, particularly xenografts, are subject to immunorejection in the absence of chronic immunosuppression. Thus, it is of great interest to develop new technologies that may be used for insulin delivery or pancreatic cell transplantation. This review describes a new approach to cellular delivery based on micro- and nanotechnology. Utilising this approach, nanoporous biocapsules are bulk and surface micromachined to present uniform and well-controlled pore sizes as small as 7 nm, tailored surface chemistries and precise microarchitectures, in order to provide immunoisolating microenvironments for cells. Such a design may overcome some of the limitations associated with conventional encapsulation and delivery technologies, including chemical instabilities, material degradation or fracture and broad membrane pore sizes.
Author Desai, Tejal A
Author_xml – sequence: 1
  givenname: Tejal A
  surname: Desai
  fullname: Desai, Tejal A
  email: Tdesai@uic.edu
  organization: Department of Biomedical Engineering, Boston University, MA 02215, USA. Tdesai@uic.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/12171507$$D View this record in MEDLINE/PubMed
BookMark eNo1jztPwzAUhT0U0QfsTCh_IMHXSfwYGFAFBamIBebq-tqGoNSOnHTov4fymI70nU9HOks2iyl6xq6AV9CCuoFGgWiNrkQlK1nXM7Y4ofLE5mw5jp-cC25acc7mIEBBy9WC3T53lFNAmzvCqUuxmDx9xNSn92MRUi4GjJT9d0UF-b4vfCQcxkP_I1-ws4D96C__csXeHu5f14_l9mXztL7bllQbPZUOlDTYIDlAraWxzkuQTjYaiZPCVujaKBGM9eg0BcuVlE0IwZI1QUixYte_u8PB7r3bDbnbYz7u_n-IL8RTS38
CitedBy_id crossref_primary_10_1021_jp045478u
crossref_primary_10_1089_dia_2005_7_684
crossref_primary_10_1039_b806446f
crossref_primary_10_1016_j_biomaterials_2006_07_010
crossref_primary_10_1163_092050609X12567186470615
crossref_primary_10_1039_c2cc17690d
crossref_primary_10_1002_cmr_b_10073
crossref_primary_10_1007_s11029_011_9184_z
crossref_primary_10_1016_j_jconrel_2004_09_024
crossref_primary_10_1039_c2jm30888f
crossref_primary_10_1002_adbi_201900086
crossref_primary_10_1039_c0lc00499e
crossref_primary_10_1039_c2jm16819g
crossref_primary_10_1039_c3ib20226g
crossref_primary_10_1002_mabi_201200012
crossref_primary_10_1007_s10544_006_0032_1
crossref_primary_10_1016_j_tibtech_2007_09_006
crossref_primary_10_1093_icb_icr010
crossref_primary_10_1016_j_medcli_2010_12_005
crossref_primary_10_1016_j_tibtech_2004_05_005
crossref_primary_10_1071_CH06197
crossref_primary_10_1007_s13410_017_0558_1
crossref_primary_10_1002_adma_200602574
crossref_primary_10_1038_nm0103_104
crossref_primary_10_1517_17425247_2015_961420
crossref_primary_10_1007_s10439_005_9008_1
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1517/14712598.2.6.633
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 12171507
Genre Research Support, U.S. Gov't, Non-P.H.S
Review
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
00X
03L
0BK
0R~
0VX
29G
4.4
53G
5GY
AAMIU
AAOUU
AAPWH
ABBAB
ABEIZ
ABJNI
ABJYH
ABLIJ
ABLKL
ABVAX
ABXYU
ACGFS
ACIEZ
ADCVX
ADRBQ
ADTOD
AECIN
AENEX
AEOZL
AGDLA
AGMLL
AIJEM
AIRBT
AIYSM
AIZAD
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
BABNJ
BLEHA
CAZVN
CCCUG
CGR
CS3
CUY
CVF
DASJU
DAWQK
DKSSO
DU5
EBS
ECM
EIF
EJD
F5P
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
LJTGL
M44
M4Z
NPM
O9-
P2P
RNANH
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUROJ
TZHSB
V1S
~1N
ID FETCH-LOGICAL-c398t-d1769a4acd1a8869bde616d648ac0c7a5283972f9bead8cfb07664fffbcb9f262
ISSN 1471-2598
IngestDate Tue Oct 15 23:23:04 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c398t-d1769a4acd1a8869bde616d648ac0c7a5283972f9bead8cfb07664fffbcb9f262
PMID 12171507
ParticipantIDs pubmed_primary_12171507
PublicationCentury 2000
PublicationDate 2002-Aug
PublicationDateYYYYMMDD 2002-08-01
PublicationDate_xml – month: 08
  year: 2002
  text: 2002-Aug
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Expert opinion on biological therapy
PublicationTitleAlternate Expert Opin Biol Ther
PublicationYear 2002
SSID ssj0020952
Score 1.7887833
SecondaryResourceType review_article
Snippet The inadequacy of conventional insulin therapy for the treatment of Type I diabetes has stimulated research on several therapeutic alternatives, including...
SourceID pubmed
SourceType Index Database
StartPage 633
SubjectTerms Animals
Biocompatible Materials
Cell Transplantation - methods
Diabetes Mellitus, Type 1 - therapy
Diffusion
Drug Delivery Systems
Humans
Insulin - administration & dosage
Insulin Infusion Systems
Insulinoma - metabolism
Islets of Langerhans - cytology
Microscopy, Electron, Scanning
Pancreas - cytology
Time Factors
Title Microfabrication technology for pancreatic cell encapsulation
URI https://www.ncbi.nlm.nih.gov/pubmed/12171507
Volume 2
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ07T8MwEMctHgsL4v1GHlCXNCFJUzsZEQJVSEUdUqlbZTv2UEGpSpby6TnbebQpiMcSRXFkufdrnLuL72-EbiQ4HWG3w11fxtyNdBFXzJVwaRBSweEdz02Fd_-Z9IbR06g7qncUNNUlOffEx5d1Jf-hCteAq66S_QPZqlO4AOfAF45AGI6_YtzXq-kU4_Mi8ebkVaLcLB-EJ906hcLRCXoHxs4gKn6paUyqlXhynju6eMo4kFPHijMZgvmq8ABEqnYL61RONN-VvEFYrVorpzp4LbkQ_MTLc2G4hHx5XiNWrWJtvu0GtmIf0EJPXugRr3ErWGz2auwfQPSj3c-fWxsK2GXTJtqEWEBvbqozMkVQDS6i-aJd_priUzQM7LY5LC0QW3TVCCKMM5Huod0iCsB3Fuk-2pDTA9QaWBnxRRundVXcexu38KAWGF8cojXuuOaOgTuuuWPNHa9wP0LDx4f0vucW22C4opPEuZsFlCQsYiILWByThGeSBCQjUcyELyjT8jwJDVXCYVaIheI-JSRSSnHBExWS8BhtTd-m8hRhFSiq9YKSTLAoSCSLqE8y5lMBVumQ7AydWLOMZ1brZFwa7Pzblgu0U_-9LtG2godLXoGnlvNrg-oTXEY8SA
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Microfabrication+technology+for+pancreatic+cell+encapsulation&rft.jtitle=Expert+opinion+on+biological+therapy&rft.au=Desai%2C+Tejal+A&rft.date=2002-08-01&rft.issn=1471-2598&rft.volume=2&rft.issue=6&rft.spage=633&rft_id=info:doi/10.1517%2F14712598.2.6.633&rft_id=info%3Apmid%2F12171507&rft_id=info%3Apmid%2F12171507&rft.externalDocID=12171507
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2598&client=summon